Tisleizumab(BGB-A317)

Phase 2Small molecule

SSun Yat-sen University

Tisleizumab(BGB-A317) is one of 11 small molecule programs targeting HER2 Positive. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HER2 PositiveNot yet recruiting

Refractory Solid Cancer Patients Unexposed to ImmunotherapyNot yet recruiting

HER2 PositivePhase 2

Not yet recruiting

Refractory Solid Cancer Patients Unexposed to ImmunotherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

14 competitors in HER2 Positive

#DrugCompanyPhaseTrials

Zaniducla

Jazz Pharmaceuticals

Phase 2

2 2

Eloxatin

Teva

Phase 2

2 3

Gemzar

Johnson & Johnson

Phase 2

1 4

Beyfortus

BeiGene

Phase 2

1 5

Abraxane

Bristol-Myers Squibb

Phase 2

1 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

3 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 8

S-1

Taiho Oncology, Inc.

Phase 2

1 9

Tisleizumab(BGB-A317)

SSun Yat-sen University

Phase 2

1 10

T-Dxd

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Refractory Solid Cancer Patients Unexposed to Immunotherapy

NCT07300891

Q2 2031

Phase 2Not yet recruiting

HER2 Positive

NCT07243938

Clinical

Trials by Indication[1]

Neoadjuvant1 trial

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Unknown status·SSun Yat-sen University·Phase 2·NCT06262581·40 enrolled

Refractory Solid Cancer Patients Unexposed to Immunotherapy1 trial

T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy

Not yet recruiting·SSamsung Medical Center·Phase 2·NCT07300891·72 enrolled

HER2 Positive1 trial

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Not yet recruiting·TTao Zhang·Phase 2·NCT07243938·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Tisleizumab(BGB-A317). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tisleizumab(BGB-A317) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tisleizumab(BGB-A317). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Tisleizumab(BGB-A317)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2031

Trials by Indication[1]

Neoadjuvant1 trial

Refractory Solid Cancer Patients Unexposed to Immunotherapy1 trial

HER2 Positive1 trial

References

Drug Info

Quick Facts

Related News